ABSTRACT
Meningococcal infections that have high mortality and morbidity in childhood and progress rapidly are an important health problem. It is one of the most important emergent diseases of the infectious diseases. Neisseria meningitidis has 13 serogroups. A, B, C, Y and W135 are the most common cause of invasive diseases among these serogroups. The outcome of meningococcal disease is dependent on the immediate recognition of two major complications: Shock and increased intracranial pressure syndrome. Rapid recognition of the disease and these complications are very important for the outcome of affected patients with appropriate treatment. Our case is a 6-month-old girl who presented with fever, malaise and a rapidly spreading rash all over the body. Septic shock due to meningocoxemia was considered because of the typical rash, weakness, susceptibility to sleep and low blood pressure. This case report includes a review of septic shock therapy due to meningococemia in a patient who was diagnosed with invasive meningococcal disease and died despite rapid and appropriate treatment methods.
Keywords: Meningococcemia, child, septic shock
References
1
Kaplan SL, Schutze GE, Leake JA, Barson WJ, Halasa NB, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979-84.
2
Kendirli T, Yıldızdaş D, Boşnak M, Köroglu T, Duman M , ve ark. Çocuk Yoğun Bakım Ünitelerinde Meningokoksemi: Demografik, Epidemiyolojik ve Klinik Özellikler. J Pediatr Emerg Intens Care Med. 2015;2:7-12.
3
Hazelzet JA. Diagnosing meningococcemia as a cause of sepsis. Pediatr Crit Care Med. 2005;6(3 Suppl):S50-4.
4
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378-88.
5
Theilen U, Wilson L, Wilson G, Beattie JO, Qureshi S, et al. Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines. BMJ. 2008;336:1367-70.
6
Maat M, Buysse CM, Emonts M, Spanjaard L, Joosten KF, et al. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care. 2007;11:R112.
7
Tzeng YL, Stephens DS. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2000;2:687-700.
8
Kepenekli E, Tuygun N, Tanır G. Çocuklarda invazif Meningokokkal Hastalık 7 Hastada Klinik Özellikler ve Tedavi Yaklaşımının Değerlendirilmesi. J Pediatr Inf. 2008;2:152-5.
9
Beran O, Lawrence DA, Andersen N, Dzupova O, Kalmusova J, et al. Sequential analysis of biomarkers in cerebrospinal fluid and serum during invasive meningococcal disease. Eur J Clin Microbiol Infect Dis. 2009;28:793-9.
10
Alhan E, Bozdemir N, Yüksel B, Onenli N, Kocabaş E, ve ark. Epidemiology of meningococcal infections in children in mid-southern part of Turkey. Eur J Epidemiol. 1995;11:393-6.
11
Malley R, Huskins WC, Kuppermann N. Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. J Pediatr. 1996;129:702-10.
12
Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397-403.
13
Wang X, Theodore MJ, Mair R, Trujillo-Lopez E, du Plessis M, et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J Clin Microbiol. 2012;50:702-8.
14
Tolaj I, Ramadani H, Mehmeti M, Gashi H, Kasumi A, et al. Does Dexamethasone Helps in Meningococcal Sepsis? Med Arch. 2017;71:173-7.
15
van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9:254-63.
16
Hart CA, Thomson AP. Meningococcal disease and its management in children. BMJ. 2006;333:685-90.
17
Tolaj I, Dreshaj S, Qehaja E, Tolaj J, Doda-Ejupi T, et al. Dexamethasone as adjuvant therapy in the treatment of invasive meningococcal diseases. Med Arh. 2010;64:228-30.
18
Cornelis AS, Hachimi-Idrissi S. The use of dexamethasone in bacterial meningitis in children and adults: a retrospective analysis. ISRN Pediatr. 2011;2011:380283.
19
Sinha R, Nadel S. Understanding shock. Paediatrics Child Health. 2013;23:187-93.
20
Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020;46(Suppl 1):10-67.
21
Duman M, Şevketoğlu E, Arslanköylü AE. Çocuklarda sepsis ve septik şok protokolü 2018. www.cayd.org.tr/yayınlar/protokoller.
22
Yıldızdaş D, Yapıcıoğlu H, Tümgör G, Erbe F. Çocuk yoğun bakım ünitesi’nde sepsis nedeni ile izlenen hastalarda poliklonal intravenöz immünglobülin tedavisi mortaliteyi azaltıyor mu? Çocuk Sağlığı ve Hastalıkları Dergisi. 2005;48:136-41.
23
El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005;51:271-8.
24
Guo XH, Sun YF, Han SZ, Miao J, Cui M, et al. Continuous blood purification in children with severe sepsis. J Biol Regul Homeost Agents. 2017;31:389-94.
25
Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010;55:316-25.
26
Gulla KM, Sachdev A, Gupta D, Gupta N, Anand K, et al. Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction - A pilot study on timing of initiation. Indian J Crit Care Med. 2015;19:613-7.
27
Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18:699.
28
Sevketoglu E, Yildizdas D, Horoz OO, Kihtir HS, Kendirli T, et al. Use of therapeutic plasma exchange in children with thrombocytopenia-associated multiple organ failure in the Turkish thrombocytopenia-associated multiple organ failure network. Pediatr Crit Care Med. 2014;15:e354-9.
29
Nasr VG, Raman L, Barbaro RP, Guner Y, Tonna J, et al. Highlights from the Extracorporeal Life Support Organization Registry: 2006-2017. ASAIO J. 2019;65:537-44.
30
Maclaren G, Butt W, Best D, Donath S, Taylor A. Extracorporeal membrane oxygenation for refractory septic shock in children: one institution’s experience. Pediatr Crit Care Med. 2007;8:447-51.
31
Barbaro RP, Xu Y, Borasino S, Truemper EJ, Watson RS, et al. Does Extracorporeal Membrane Oxygenation Improve Survival in Pediatric Acute Respiratory Failure? Am J Respir Crit Care Med. 2018;197:1177-86.
32
Castellanos-Ortega A, Delgado-Rodríguez M, Llorca J, Sánchez Burón P, Mencía Bartolomé S, et al. A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems. Intensive Care Med. 2002;28:341-51.
33
Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient. J Pediatr. 1966;68:457-67.
34
Castellanos-Ortega A, Delgado-Rodríguez M. Comparison of the performance of two general and three specific scoring systems for meningococcal septic shock in children. Crit Care Med. 2000;28:2967-73.
35
Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16:1110-6.
36
Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24:743-52.
37
Shann F, Pearson G, Slater A, Wilkinson K. Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care. Intensive Care Med. 1997;23:201-7.
38
Mok Q, Butt W. The outcome of children admitted to intensive care with meningococcal septicaemia. Intensive Care Med. 1996;22:259-63.
39
Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis. 1999;28:770-7.
